Ark receives Finnish grant

The funding will be used to further develop Ark’s lentiviral vector production technology using baculoviruses (Baculo-lentiviral) to achieve required scale and GMP quality for clinical use.

Additionally, Ark has also received EUR0.2m from Finnish governmental organization Centre for Economic Development, Transport and the Environment (ELY-centre) for advancing its validation work in its Kuopio GMP3 manufacturing facility.

The support from TEKES and ELY-centre will enable this technology to be established as a production platform within Ark’s GMP manufacturing facility.

Ark Molecular Medicine consultant director Seppo Yla-Herttuala said they look forward to announcing further progress in this area in due course.